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Abstract Parathyroid hormone-related protein plays a major
role in the pathogenesis of humoral hypercalcemia of malig-
nancy. Under normal physiological conditions, parathyroid
hormone-related protein is produced in a wide variety of tissues
and acts in an autocrine or paracrine fashion. Parathyroid
hormone-related protein and parathyroid hormone bind to and
activate the same G-protein-coupled receptor. Here we present
the structure of the biologically active NH2-terminal domain of
human parathyroid hormone-related protein(1^34) in near-
physiological solution in the absence of crowding reagents as
determined by two-dimensional proton magnetic resonance
spectroscopy. An improved strategy for structure calculation
revealed the presence of two helices, His-5^Leu-8 and Gln-16^
Leu-27, connected by a flexible linker. The parathyroid
hormone-related protein(1^34) structure and the structure of
human parathyroid hormone(1^37) as well as human parathyroid
hormone(1^34) are highly similar, except for the well defined
turn, His-14^Ser-17, present in parathyroid hormone. Thus, the
similarity of the binding affinities of parathyroid hormone and
parathyroid hormone-related protein to their common receptor
may be based on their structural similarity.
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1. Introduction
Human parathyroid hormone-related peptide (hPTHrP)
was originally identi¢ed through its causative role in human
humoral hypercalcemia of malignancy (HHM) [1]. The
hPTHrP gene is thought to belong to the same family as
the parathyroid hormone (PTH) gene [1]. Unlike PTH,
PTHrP is a product of almost all normal tissues, both fetal
and adult, and plays various physiological roles in a para-
crine/autocrine fashion [2], including regulation of cellular
proliferation and di¡erentiation [3], fetus development [4], re-
production system maintenance [5], transepithelial (renal, pla-
cental, oviduct, mammary gland) calcium transport regulation
[6,7], relaxation of vascular and non-vascular smooth muscles
[8,9], calcium and phosphate homeostasis [10] and decrease of
systemic blood pressure [11]. The expression of the PTHrP
gene in normal tissues is tightly regulated by a number of
factors, involving both transcriptional and post-transcription-
al mechanisms [12^14]. PTHrP overproduced and secreted by
certain malignancies enters the circulation, interacts with a
receptor common for PTHrP and PTH, and causes hypercal-
cemia in cancer patients [1,15]. The PTH-like biological activ-
ities of the 141 amino acid PTHrP, such as stimulation of
intracellular cAMP formation, its in£uence on the serum cal-
cium level and relaxation of smooth muscle cells, are located
within the NH2-terminal 34 amino acids [1,8,16,17], in close
analogy to PTH itself. Other fragments of PTHrP, for exam-
ple from the COOH-terminus or the midregion, exert diverse
functions [1,8,16,18^22]. E¡ects of PTHrP(1^34) on its target
cells are mediated by adenylate cyclase and/or by protein kin-
ase C [15,23,24]. Recent studies imply an interaction of the
1^14 and 15^34 domains of PTHrP(1^34) on binding to the
PTH/PTHrP receptor and direct or indirect involvement of
His-5, Arg-19, and Arg-21 in this interaction [25]. The two
peptides PTH and PTHrP share eight identical amino acids in
the region 1^13, but only three identical amino acids in the
region 14^34.
The COOH-terminal domain, Ile-15^Ala-34, of hPTHrP(1^
34) is thought to be involved in receptor binding, while the
NH2-terminal domain, Ala-1^Ser-14, is suggested to trigger
the signal transduction cascade [8], analogous to the situation
in hPTH. In view of the multiple functions of hPTHrP medi-
ated by its NH2-terminal fragment 1^34, particularly its major
role in pathogenesis of humoral hypercalcemia of malignancy,
the determination of the three-dimensional structure of this
peptide is a problem of considerable biochemical and medical
interest.
Most of the hPTHrP structures were determined in solution
in the presence of 2,2,2-tri£uoroethanol (TFE), and the results
of these structure determinations di¡er in important aspects
[26^29]. Earlier work in TFE-free solution had to be partly
dismissed on grounds of misassigned proton resonances [30].
It is generally accepted that NH2-terminal fragments of
human PTH such as hPTH(1^37), hPTH(1^34), hPTH(2^
37), hPTH(3^37), hPTH(4^37), and the NH2-terminal frag-
ment of bovine PTH, bPTH(1^37), as well as several deriva-
tives obtain not only secondary structure, but also show ter-
tiary interactions in TFE-free solution ([31^34], Marx et al.,
unpublished). Due to the £exibility of the loop region around
Gly-12, however, the relative location of the two helices is not
¢xed and no overall tertiary structure is preferred ([32^34],
Marx et al., unpublished). Structural features of hPTH(1^
34) were also suggested to depend on salt concentration [34].
As the only reliable structural data of native wild-type
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hPTHrP(1^34) were determined in the presence of 50% TFE
[30], we decided to determine the structure of hPTHrP(1^34)
in near-physiological aqueous solution in the absence of
crowding reagents.
2. Materials and methods
PTHrP(1^34) was obtained as a commercial product (Neosystems,
Strasbourg).
Circular dichroism (CD) spectra were recorded at 298 K in 0.1 mm
cells from 250 to 190 nm at 20 nm/min on a Jasco 600A CD spec-
tropolarimeter with a solution of 1 mg/ml (V250 WM) peptide in
50 mM potassium phosphate, pH 5.1, 250 mM NaCl, and averaged
over 16 scans. The reference sample contained bu¡er without protein
and the instrument was calibrated with ammonium D-camphorsulfo-
nate.
For proton NMR spectroscopy, hPTHrP(1^34) was dissolved in
50 mM potassium phosphate bu¡er with 250 mM NaCl, pH 5.1, to
a ¢nal concentration of 1.5 mM. All NMR experiments were carried
out at 277 K or 298 K on a Bruker AMX600 spectrometer. Homo-
nuclear double quantum ¢ltered COSY [35], clean TOCSY with an
MLEV-17 spin-locking sequence [36], and NOESY [37] experiments
were performed in H2O/D2O (9:1) employing standard methods [38].
NOESY mixing times were 100 ms and 200 ms, and clean TOCSY
mixing times were 60 ms and 80 ms. All spectra were acquired in
phase-sensitive mode with quadrature detection in both dimensions
using the time-proportional phase incrementation technique in g1
[39]. The solvent signal was suppressed by continuous coherent irra-
diation prior to the ¢rst excitation pulse and during the mixing time
of the NOESY experiments. 4096U512 data points were collected
with a spectral width of 6024 Hz in both dimensions. Baseline correc-
tion up to sixth order was performed for all two-dimensional spectra
in both dimensions. A Z/4-shifted sinebell-squared ¢lter was used pri-
or to Fourier transformation. Zero-¢lling resulted in a data size of
4096U1024 data points in the frequency domain. The NDEE 2.0
software package (Software Symbiose, Bayreuth, Germany) was
used for data processing on Unix workstations and PCs. Chemical
shift values are reported relative to 2,2-dimethyl-2-silapentane sulfo-
nate.
For structure calculations, only NOEs visible in the 277 K spectra
with 200 ms mixing time were taken into account. Identical calcula-
tions combining information obtained at the two di¡erent tempera-
tures resulted in virtually identical structures.
An estimate of secondary structure elements can be obtained from
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Fig. 1. CD spectrum of hPTHrP(1^34) at 298 K, 1 mg/ml (V250
WM) peptide in 50 mM potassium phosphate, pH 5.1, 250 mM
sodium chloride.
Table 1
1H chemical shifts and assignments for PTHrP(1^34), 1.5 mM, at 277 K in 50 mM potassium phosphate, pH 5.1, 250 mM NaCl relative to
DSS as an external standard, þ 0.01 ppm
Residue NH KH LH QH Others
Ala-1 4.15 1.52
Val-2 8.66 4.18 2.08 0.97
Ser-3 8.64 4.45 3.92/3.85
Glu-4 8.68 4.23 1.99/1.92 2.26/2.21
His-5 8.64 4.65 3.25/3.18 8.60(2); 7.28(4)
Gln-6 8.49 4.26 2.07/2.00 2.35 7.71/7.01 (NH2)
Leu-7 8.47 4.30 1.64 1.53 0.93/0.87(N)
Leu-8 8.30 4.28 1.63/1.55 1.47 0.91/0.86(N)
His-9 8.54 4.66 3.28/3.17 8.62(2); 7.29(4)
Asp-10 8.50 4.59 2.73/2.68
Lys-11 8.53 4.28 1.91/1.83 1.47 3.01(O) ; 1.71(N)
Gly-12 8.59 3.95
Lys-13 8.23 4.36 1.88/1.79 1.48/1.41 3.00(O) ; 1.69(N)
Ser-14 8.59 4.47 4.01/3.95
Ile-15 8.40 4.05 1.91 1.52/1.25/0.93 0.88(N)
Gln-16 8.40 4.17 2.06 2.41 7.66/7.00(NH2)
Asp-17 8.36 4.53 2.74
Leu-18 8.30 4.15 1.63 0.92/0.87(N)
Arg-19 8.10 4.20 1.90/1.71 1.61 3.22(N) ; 7.33(O) ; 7.00/6.56(guanidino)
Arg-20 8.15 4.13 1.76/1.60 1.48 3.14(N) ; 7.29(O) ; 7.00/6.56(guanidino)
Arg-21 8.25 4.18 1.92/1.77 1.67 3.19(N) ; 7.42(O) ; 6.92/6.55(guanidino)
Phe-22 8.20 4.49 3.09/3.03 7.34(2,6); 7.25(3,5); 7.19(4)
Phe-23 8.25 4.48 3.20/3.06 7.34(2,6); 7.26(3,5); 7.07(4)
Leu-24 8.20 4.13 1.62 0.91/0.87(N)
His-25 8.29 4.59 3.23/3.13 8.58(2); 7.25(4)
His-26 8.35 4.60 3.21/3.01 8.53(2); 7.18(4)
Leu-27 8.35 4.29 1.62 1.54 0.90/0.84(N)
Ile-28 8.26 4.12 1.84 1.17/0.85 0.90(N)
Ala-29 8.41 4.28 1.36
Glu-30 8.39 4.23 1.96/1.90 2.28/2.20
Ile-31 8.32 4.11 1.80 1.43/1.15 0.85(N)
His-32 8.85 4.86 3.27/3.17 8.59(2); 7.28(4)
Thr-33 8.42 4.32 4.22 1.21
Ala-34 8.26 4.12 1.36
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the CK proton chemical shifts [40,41]. CKH resonances shifted to high
¢eld relative to the corresponding random coil values [42] indicate
local K-helical structure, whereas down¢eld shifted resonances are
typical for local L-sheet conformation. Elements of regular secondary
structure are assumed to be present if a deviation from the random
coil value of more than 0.1 ppm is observed. To get a more reliable
picture it is suggested that only resonances with the same sense chem-
ical shift deviation for a stretch of more than three sequential residues
are taken into account [41].
Simulated annealing (SA) and distance geometry calculations were
carried out with the XPLOR 3.840 program package [43]. Intensities
of NOESY cross-peaks were estimated from the number of contour
lines in the spectrum and divided into three distance interval classes:
strong, 0.18^0.27 nm; medium, 0.18^0.40 nm; weak, 0.18^0.55 nm.
The pseudoatom approach [44^46] was used for distances involving
unresolved resonances from methyl or methylene groups, that is, 0.05
nm was added to the upper distance limit. Frequency degenerated
NOESY cross-peaks were incorporated into the structure calculations
as ‘ambiguous’ [43]. Proton-proton distances in the calculated struc-
tures were determined using the program ‘BackCalc_db 2.0’ (Software
Symbiose, Bayreuth, Germany) and compared with the combinations
of distances possible for each frequency degenerated NOESY cross-
peak. The distance information was used in further structure calcu-
lations only if one of the possible distance combinations was ful¢lled
in more than 50% of the calculated structures. This procedure was
repeated several times.
Elements of regular secondary structure were deduced by chemical
shift analysis (cf. above) and the inspection of the NOE pattern. In
addition, the structures were checked for the existence of secondary
structural elements by MOLMOL 2.5.1 [47].
3. Results
The evaluation of the far-UV CD spectrum of the peptide
(Fig. 1) by standard methods [48,49] yielded an average helix
content of hPTHrP(1^34) of 27^37%.
Sequence-speci¢c assignments of the spin systems identi¢ed
in the COSY and TOCSY spectra could be performed with
standard techniques [38] as the spectra were well resolved
(Fig. 2, Table 1). Chemical shift data of the CKH resonances
were analyzed according to the chemical shift index strategy
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Fig. 2. Fingerprint region of the NOESY spectrum of hPTHrP(1^34), 1.5 mM, at 277 K in 50 mM potassium phosphate, pH 5.1, 250 mM so-
dium chloride.
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[41,42], yielding an estimate of elements of regular secondary
structure (Fig. 3A). An K-helical stretch from Ile-15 to Leu-27
is clearly suggested, and a short helix around Glu-6 may also
be deduced (Fig. 3A). This preliminary estimate was con-
¢rmed and re¢ned by analysis of NOESY cross-peak patterns
(Fig. 3B). According to this data, hPTHrP(1^34) forms two
helical stretches, a short helix near the NH2-terminus, His-5^
Asp-10, and a longer COOH-terminal helix, Ser-14^Ala-29.
424 intraresidual and 337 interresidual NOE connectivities
(Table 2) were used in an SA protocol with subsequent re¢ne-
ment to generate 100 structures from an elongated starting
conformation. The 30 structures with lowest total energies
were superimposed, and the local root mean square deviation
of the backbone atoms was calculated with a seven residue
window. The two regions representing helices as judged from
the chemical shift and NOE data, His-5^Asp-10 and Ser-14^
Ala-29, were well de¢ned (Fig. 3C) and connected by a £exible
linker. The short NH2-terminal helix, His-5^Leu-8, is present
in 60% of the structures, and COOH-terminal K-helix is
present in all calculated structures. The core sequence of
this helix is formed by residues Gln-16^His-26, but the helix
extends from Ser-14 to Leu-27 in some structures (Fig. 4).
NOESY cross-peaks could be observed between the terminal
methyl groups of Ile-15 and the guanidine group of Arg-21.
These, however, proved to be insu⁄cient to de¢ne even a
locally stable tertiary fold.
4. Discussion
The hPTHrP(1^34) structure determined here and the struc-
ture of hPTH(1^37) as well as hPTH(1^34) in TFE-free sol-
ution ([32], Marx et al., unpublished) are highly similar, ex-
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Fig. 3. A: Chemical shift plot of N(CKH, peptide)/N(CKH, random coil) according to Wishart et al. [41,42]. B: Pattern of sequential and me-
dium range NOESY connectivities versus peptide sequence. The height of the bars corresponds to the relative intensity of the NOESY cross-
peaks. C: Local RMSD values calculated with a seven amino acid window. The plot was calculated on the basis of the 30 ¢nal structures of
PTHrP(1^34). Upper trace: all heavy atoms. Lower trace: backbone atoms.
Table 2
NOE restraints, energy contributions and deviations from standard
geometry
No. of NOEs
Total 761
Mi3jM=0 424
Mi3jM=1 185
Mi3jM=2, 3, 4, 5 149
Mi3jMs 5 3
Rmsd from ideality after SA re¢nement with X-PLOR
NOEs (nm) 0.00516
Angles (deg) 0.66706
Bonds (nm) 0.00062
Impr (deg) 0.62933
Average energies (kJ/mol) after SA re¢nement with X-PLOR
Eoverall 981.57
Ebonds 93.71
Eangles 296.38
ENOE 424.59
Rmsd among backbone structures (nm) after SA re¢nement with
X-PLOR
Ser-14^Leu-27 0.043
Gln-16^His-26 0.022
Whole protein 0.401
NOE violations: three of the 30 lowest energy structures show a single
NOE violation.
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cept for the well de¢ned turn, His-14^Ser-17, that in combi-
nation with a £exible link connects the two K-helices in hPTH.
This is compatible with the observation that the two peptides
are able to bind to the same receptor with comparable a⁄n-
ities [50]. As hPTH and hPTHrP show only 15.8% homology
in the stretch Leu-15^Phe-34 that is thought to be responsible
for receptor binding, this might indicate structure-based pep-
tide-receptor recognition. No indication for interactions be-
tween the two helices of hPTHrP(1^34), His-5^His-9 and
Ser-14^Leu-27 according to the MD calculations, was ob-
served. In contrast, a hydrophobic core and a £exible hinge
are present between these helices in (Ala-26)hPTHrP(1^34) in
the presence of TFE [27]. Hydrophobic interactions should be
more favorable under the present, TFE-free solution condi-
tions than in the presence of TFE [32,51^53], but the salt
bridge between Arg-20 and Glu-30 [27] may be stabilized in
TFE-containing bu¡er as a consequence of the reduced dielec-
tric constant of the solution. This salt bridge, not observable
under the current near physiological conditions, results in
spatial proximity of the residues suggested to form the hydro-
phobic core.
In contrast to hPTH NH2-terminal fragments, hPTHrP(1^
34) does not show tertiary interactions between residues Ile-15
and Phe-23. Whereas the COOH-terminal helix in the hPTH
fragments starts at position 17, this helix starts at position 14/
15 in the hPTHrP fragment. Thus, in hPTHrP, Ile-15 is in-
volved in a stable regular secondary structure that does not
allow interaction with Phe-23. The COOH-terminal helix in
hPTHrP(1^34) starts close to Ser-14, which may well serve as
a helix cap. The analogous residue in hPTH is Ser-17, render-
ing a shift of the helix start of three residues from the NH2-
terminus.
The absence of any indication for interactions between the
two helices does not rule out the possibility that such an
interaction is induced or stabilized upon binding to the recep-
tor, as proposed recently [25]. Indeed, the structure presented
here would enable the two helices to interact upon receptor
binding as they are only connected via the £exible loop
around Gly-12. PTHrP(14^34) is still able to bind to the
PTH/PTHrP receptor, albeit weakly [54], whereas peptide
fragments containing only the NH2-terminal amino acids do
not show any biological activity [55]. The COOH-terminal
helix is essential for receptor binding, while the signal trans-
duction cascade is triggered by the NH2-terminal part [56]. It
may thus be speculated that initial receptor binding of the
COOH-terminal helix facilitates receptor interaction with the
NH2-terminal helix. Alternatively, interaction between the
two helices of the peptide may be necessary for activity and
may be induced upon receptor binding [25].
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